Levothyroxine Supplementation for Heart Transplant Recipients
Levothyroxine Supplementation for Heart Transplant Recipients: A Randomized Control Trial
University of California, San Francisco
97 participants
Mar 29, 2024
INTERVENTIONAL
Conditions
Summary
This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.
Eligibility
Inclusion Criteria3
- Participants must be listed for heart transplantation
- Age ≥18 years
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria3
- Patients with pre-existing thyroid related condition including hypothyroidism, hyperthyroidism and malignancy
- Patients with a known allergy or intolerance to levothyroxine
- Patients participating in another study evaluating an investigational drug within the past 30 days.
Interventions
Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06428097